Ambrx Biopharma Inc. (NYSE:AMAM – Get Free Report) shares were up 4.6% during mid-day trading on Friday . The stock traded as high as $13.95 and last traded at $13.68. Approximately 74,018 shares changed hands during trading, a decline of 96% from the average daily volume of 2,020,325 shares. The stock had previously closed at $13.08.
Analysts Set New Price Targets
Several equities analysts recently issued reports on AMAM shares. Royal Bank of Canada started coverage on Ambrx Biopharma in a research report on Monday, July 31st. They set an “outperform” rating and a $29.00 price target on the stock. B. Riley initiated coverage on Ambrx Biopharma in a research note on Tuesday, June 13th. They issued a “buy” rating and a $26.00 target price for the company. Cantor Fitzgerald reiterated an “overweight” rating and set a $25.00 price objective on shares of Ambrx Biopharma in a research note on Wednesday, August 16th. Finally, Oppenheimer assumed coverage on Ambrx Biopharma in a report on Thursday, June 1st. They issued an “outperform” rating and a $30.00 price objective for the company. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, Ambrx Biopharma currently has an average rating of “Moderate Buy” and a consensus target price of $21.33.
Ambrx Biopharma Stock Performance
Hedge Funds Weigh In On Ambrx Biopharma
Several institutional investors have recently bought and sold shares of AMAM. Exchange Traded Concepts LLC purchased a new stake in shares of Ambrx Biopharma during the 2nd quarter valued at about $162,000. Tocqueville Asset Management L.P. bought a new position in Ambrx Biopharma in the 1st quarter worth about $112,000. QP Wealth Management LLC bought a new position in Ambrx Biopharma in the 2nd quarter worth about $209,000. Innovis Asset Management LLC bought a new position in Ambrx Biopharma in the 2nd quarter worth about $277,000. Finally, Squarepoint Ops LLC bought a new position in Ambrx Biopharma in the 1st quarter worth about $156,000.
Ambrx Biopharma Company Profile
Ambrx Biopharma Inc, a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform. The company's lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated in various clinical trials for the treatment of breast cancer, gastric/gastroesophageal junction cancer, and other solid tumors, including ongoing Phase 2/3 clinical trials for the treatment of HER2-positive metastatic breast cancer and gastric cancer.
- Five stocks we like better than Ambrx Biopharma
- Comparing and Trading High PE Ratio Stocks
- 2 Stocks to Get You Ready for the Holiday Season
- How to Invest in Social Media
- Profit Potential: 5 Undervalued Stocks With High Dividend Yields
- How to Start Investing in Real Estate
- MarketBeat Week in Review – 8/21 – 8/25
Receive News & Ratings for Ambrx Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ambrx Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.